These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 8258521)

  • 1. Complete elimination ('cure') of progressively growing intraocular tumors by local injection of tumor-specific CD8+ T lymphocytes.
    Miki S; Ksander B; Streilein JW
    Invest Ophthalmol Vis Sci; 1993 Dec; 34(13):3622-34. PubMed ID: 8258521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on the minimum requirements for in vitro "cure" of tumor cells by cytotoxic T lymphocytes.
    Miki S; Ksander B; Streilein JW
    Reg Immunol; 1992; 4(6):352-62. PubMed ID: 1297406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infiltration and accumulation of precursor cytotoxic T-cells increase with time in progressively growing ocular tumors.
    Ksander BR; Bando Y; Acevedo J; Streilein JW
    Cancer Res; 1991 Jun; 51(12):3153-8. PubMed ID: 1904003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure of infiltrating precursor cytotoxic T cells to acquire direct cytotoxic function in immunologically privileged sites.
    Ksander BR; Streilein JW
    J Immunol; 1990 Oct; 145(7):2057-63. PubMed ID: 1975822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines.
    Chen PW; Ksander BR
    Curr Eye Res; 2006 Jan; 31(1):43-55. PubMed ID: 16421019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vivo impaired T helper 1 cell development in submandibular lymph nodes due to IL-12 deficiency following antigen injection into the anterior chamber of the eye.
    Perez VL; Biuckians AJ; Streilein JW
    Ocul Immunol Inflamm; 2000 Mar; 8(1):9-24. PubMed ID: 10806431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful immunotherapy of an intraocular tumor in mice.
    Schurmans LR; den Boer AT; Diehl L; van der Voort EI; Kast WM; Melief CJ; Toes RE; Jager MJ
    Cancer Res; 1999 Oct; 59(20):5250-4. PubMed ID: 10537305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
    Inoue M; Plautz GE; Shu S
    Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local T helper cell signals by lymphocytes infiltrating intraocular tumors.
    Ksander BR; Acevedo J; Streilein JW
    J Immunol; 1992 Mar; 148(6):1955-63. PubMed ID: 1531848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of cytotoxic T cell responses to intracameral allogeneic tumors.
    Ksander BR; Streilein JW
    Invest Ophthalmol Vis Sci; 1989 Feb; 30(2):323-9. PubMed ID: 2492486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of specific T helper cell activity in mice bearing alloantigenic tumors in the anterior chamber of the eye.
    Bando Y; Ksander BR; Streilein JW
    Eur J Immunol; 1991 Aug; 21(8):1923-31. PubMed ID: 1831132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive transfer of immunity to intraocular tumors in mice.
    Niederkorn JY; Streilein JW
    Invest Ophthalmol Vis Sci; 1984 Mar; 25(3):336-42. PubMed ID: 6421767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapeutic elimination of syngeneic tumors in vivo by cytotoxic T lymphocytes generated in vitro from lymphocytes from the draining lymph nodes of tumor-bearing mice.
    Lynch DH; Miller RE
    Eur J Immunol; 1991 Jun; 21(6):1403-10. PubMed ID: 1904359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Requirement of CD80+ costimulation for rejection of ocular tumors and termination of immune privilege.
    Chen PW; Uno T; Ksander BR
    Exp Eye Res; 2006 Sep; 83(3):574-83. PubMed ID: 16643898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune privilege is extended, then withdrawn, from allogeneic tumor cell grafts placed in the subretinal space.
    Wenkel H; Chen PW; Ksander BR; Streilein JW
    Invest Ophthalmol Vis Sci; 1999 Dec; 40(13):3202-8. PubMed ID: 10586943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recovery of activated cytotoxic T cells from minor H incompatible tumor graft rejection sites.
    Ksander BR; Streilein JW
    J Immunol; 1989 Jul; 143(2):426-31. PubMed ID: 2500481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
    Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD
    Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
    Utermöhlen O; Schulze-Garg C; Warnecke G; Gugel R; Löhler J; Deppert W
    J Virol; 2001 Nov; 75(22):10593-602. PubMed ID: 11602701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired induction of delayed hypersensitivity following anterior chamber inoculation of alloantigens.
    Williamson JS; Streilein JW
    Reg Immunol; 1988; 1(1):15-23. PubMed ID: 2978942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of tumor-infiltrating lymphocytes in the treatment of hepatic metastases arising from transgenic intraocular tumors in mice.
    Ma D; Niederkorn JY
    Invest Ophthalmol Vis Sci; 1995 May; 36(6):1067-75. PubMed ID: 7730016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.